Global Medical LeadSobi, Stockholm, SwedenSolna, Stockholms Lan, Sweden
PB0209 - Effectiveness and safety of efmoroctocog alfa (a recombinant factor VIII Fc) across body mass index (BMI) categories: pooled data from two non-interventional phase 4 studies (A-SURE/PREVENT)
Sunday, June 23, 202413:45 – 14:45 ICT
PB0505 - Long-term joint health outcomes with a recombinant factor VIII Fc from the 48-month prospective, observational A-MORE study: Third interim analysis of up to 24 months
Monday, June 24, 202413:45 – 14:45 ICT
